Business
Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers
INT230-6 Induced T-Cell Receptor Signaling, Macrophage Markers, and IL-18 and B-Cell Receptor Signaling Data Was Presented at the 2023 American Society of
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"INT230-6 Induced T-Cell Receptor Signaling, Macrophage Markers, and IL-18 and B-Cell Receptor Signaling\nData Was Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2023\nWESTPORT, Conn., June 6, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (\"Intensity\"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral (IT) cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its INVINCIBLE study was presented on June 4, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.\nThe INVINCIBLE study is a phase 2, randomized, open label, multi-center study that enrolled 91 women with newly diagnosed operable early-stage intermediate or high-grade T1-T2 invasive breast cancers who were randomly allocated (2:1) prior to resection to IT injections of INT230-6, no treatment or saline sham injection. The study is evaluating clinical and biological effects in patients with early-stage operable breast cancer. The study presented new immune and gene activation related results as well as data demonstrating efficacy and tolerability of INT230-6.\nAbstract Title: A phase 2 randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE Trial.First Author: Angel Arnaout, MD, FACSSession Type/Title: Poster Session/Breast Cancer—Local/Regional/AdjuvantSession Date and Time: Sunday, June 4, 2023, 9:00 AM - 12:00 PM EDTLocation: In-Person & On DemandAbstract Number: 573Poster: 403\nCopies of the presentation materials are available on Intensity's website on the publications, papers and posters page.\n\"For the majority of breast cancer patients, the typical waiting period of 2-6 weeks from diagnosis to surgery is a very fearful time. Surgeons and patients feel powerless, as there are currently no therapeutic options for the patient prior to the surgery,\" said Angel Arnaout, M.D., Scientist and Surgical Oncologist at the Ottawa Hospital, and Professor of Surgery at the University of Ottawa and Co-lead of the Ontario Institute for Cancer Research (OICR) WOO Network. \"We have previously reported that the ...